Clinical Trials · NCT01473953
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 31
- Start date
- Oct 2011
- Locations
- 1 site, United States
- Primary endpoint
- Number of Treatment Emergent Adverse Events (TEAEs)